EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Predictive Oncology's enterprise value is $-0.43 Mil.
Predictive Oncology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-13.18 Mil. Therefore, Predictive Oncology's EV-to-EBITDA for today is 0.03.
The historical rank and industry rank for Predictive Oncology's EV-to-EBITDA or its related term are showing as below:
POAI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -13.45 Med: -1.51 Max: 0.91
Current: 0.03
During the past 13 years, the highest EV-to-EBITDA of Predictive Oncology was 0.91. The lowest was -13.45. And the median was -1.51.
POAI's EV-to-EBITDA is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 15.69
vs POAI: 0.03
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Predictive Oncology EV-to-EBITDA Historical Data
The historical data trend for Predictive Oncology's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Predictive Oncology's EV-to-EBITDA
For the Medical Instruments & Supplies subindustry, Predictive Oncology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Predictive Oncology's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Predictive Oncology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Predictive Oncology's EV-to-EBITDA falls into.
Predictive Oncology's current Enterprise Value is $-0.43 Mil.
Predictive Oncology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Predictive Oncology's PE Ratio for today is calculated as:
Predictive Oncology's share price for today is $1.41.
Predictive Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.470.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Predictive Oncology's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Predictive Oncology (Predictive Oncology) Business Description
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
POAI has been successfully added to your 